Wed, February 21, 2018
Tue, February 20, 2018
Fri, February 16, 2018
Thu, February 15, 2018

David Nierengarten Maintained (ANAB) at Buy with Increased Target to $151 on, Feb 20th, 2018

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-increased-target-to-151-on-feb-20th-2018.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
David Nierengarten of Wedbush, Maintained "AnaptysBio, Inc." (ANAB) at Buy with Increased Target from $142 to $151 on, Feb 20th, 2018.

David has made no other calls on ANAB in the last 4 months.



There are 2 other peers that have a rating on ANAB. Out of the 2 peers that are also analyzing ANAB, 0 agree with David's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with David


  • Yatin Suneja of "SunTrust Robinson Humphrey" Initiated at Strong Buy and Held Target at $115 on, Wednesday, November 15th, 2017
  • Biren Amin of "Jefferies" Initiated at Strong Buy and Held Target at $101 on, Thursday, November 9th, 2017